

IDS - 12/29/2003

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

91

Complete if Known	
Application Number	
Filing Date	12/29/03
First Named Inventor	Stephen Eliot Zweig
Art Unit	
Examiner Name	
Attorney Docket Number	

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (If known)			
JL	WIPO WO0125472A1				

**Examiner
Signature**

/Jerry Lin/

Date Considered

08/14/2006

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **¹Applicant's unique citation designation number (optional).** **²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.** **³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).** **⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.** **⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.** **⁶Applicant is to place a check mark here if English language Translation is attached.**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	
			Filing Date	12/29/03
			First Named Inventor	Stephen Eliot Zweig
			Art Unit	
Sheet 1 of 1	Examiner Name			
Sheet 1 of 1	Attorney Docket Number			

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
JL		Rosenberg, Immunogenicity of Biological Therapeutics, A Hierarchy of Concerns, Dev. Biol. Basel, Karger 2003, Vol 112, pp15-21		
		Chamberlain, "Immunogenicity of Therapeutic Proteins", The Regulatory Review 5:5, August 2002., pp 4-9		
		Hochuli, "Interferon Immunogenicity: Technical Evaluation of Interferon •2•", J. Interferon and Cytokine Res. 17 supplement 1: S15-S21, 1997		
		DePaolis et. al., "Characterization of erythropoietin dimerization", J Pharm Sci. 1995 Nov;84(11):1280-4		
		Haselbeck, "Epoetins: differences and their relevance to immunogenicity", Current Medical Research and Opinions 19(5), p 430-432 (2003)		

Examiner Signature	/Jerry Lin/	Date Considered	08/14/2006
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.